1
|
Zenner BP, Schmitz D, Zenner HP, Wirth M. [Structured ABEV Exercises for the Treatment of vestibular dysfunction]. Laryngorhinootologie 2024; 103:207-212. [PMID: 37678393 DOI: 10.1055/a-2135-5762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/09/2023]
Abstract
INTRODUCTION In addition to medication, the standard clinical treatment for vestibular vertigo primarily includes physical therapy in the form of regular exercises. Vertidisan is a future digital health application (DiGA) for structured dizziness therapy. Its content is multimodal and consists of Adaptive Balance and Eye Movements and Visual Stimulation (ABEV) exercises, which are expected to have an anti-vertigo effect through neural learning. METHODS A cohort study with 104 patients with intra-individual control was conducted to examine the clinical efficacy of solely 16 ABEV exercises for the treatment of peripheral vestibulopathies which are also used digitally in the future DiGA Vertidisan. Using the short version vertigo symptom scale short form1 vertigo and related symptoms (VSS-sf1-VER) of the vertigo-specific and validated VSS rating scale (Vertigo Symptom Scale) as the primary outcome variable, the vertigo scores before therapy (time T0) were compared with the corresponding data at the end of a period of 12-16 weeks (time T1). RESULTS Complete datasets on T0 and T1 were available for N=104 patients. The mean VSS-sf1-V score decreased from 3.80 (median 4, SD 0.47) to 0.92 (median 1, SD 1.19) from T0 to T1 (weeks 12-16). The result is statistically significant (p=0.001) and shows a high clinical effect size. CONCLUSION In summary, the analysis of the dizziness score shows a statistically and clinically significant reduction in dizziness through the use of the 16 ABEV exercises.
Collapse
Affiliation(s)
- Benedikt P Zenner
- Institut für Health Care und Public Management, Universität Hohenheim, Stuttgart, Germany
| | | | - Hans-Peter Zenner
- Universitätsklinik für Hals-Nasen-Ohren-Heilkunde, Eberhard-Karls-Universität Tübingen, Medizinische Fakultät, Tübingen, Germany
| | - Markus Wirth
- Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde, Klinikum rechts der Isar der Technischen Universität München, München, Germany
| |
Collapse
|
2
|
Abstract
Local therapy of middle and inner ear diseases is being used, but is restricted to cases of ear drum perforation or to repeated invasive intratympanic drug application by the physician. In accordance with the Medical Device Directive (class III), a bone-anchored, totally implantable drug delivery system (TI-DDS) has been developed. It includes a micropump for subcutaneous, patient-controlled activation, a drug reservoir and a septum port. A thin guide-wired catheter leads from the pump outlet to the point of application in the mastoid or middle ear cavities. Local inner ear therapy with suitable drugs is possible by positioning the catheter's end near the round window membrane. The system requires no battery and will offer a wide range of patient-controlled bolus applications (25 μl per activation). We first analyzed the three-dimensional implantation geometry of the mastoid cavity. Basic micromechanical problems have been solved in order to create several prototypes. The TI-DDS has already undergone extensive in vitro testing. Recent results of pump rate precision and digital pressure force testing are promising. Local drug treatment for conditions such as lidocaine-sensitive tinnitus, secretory otitis media, Meniere's disease, localized pain and intralesional cancer is under discussion. Furthermore, local application of future biotechnological trophic factors for inner ear treatment is anticipated. The basic engineering is completed and initial animal tests are in preparation.
Collapse
Affiliation(s)
- Rolf Lehner
- From the University of Tübingen, Department of Otolaryngology, Tübingen, Germany
| | - Heribert Brugger
- From the University of Tübingen, Department of Otolaryngology, Tübingen, Germany
| | - Marcus M. Maassen
- From the University of Tübingen, Department of Otolaryngology, Tübingen, Germany
| | - Hans-Peter Zenner
- From the University of Tübingen, Department of Otolaryngology, Tübingen, Germany
| |
Collapse
|
3
|
Holderried M, Tenk S, Zenner HP, Ernst C, Häberle H, Maschmann J. [Structuring of inpatient case management to improve quality and cost-effectiveness of inpatient healthcare providers from a university hospital's point of view]. Z Evid Fortbild Qual Gesundhwes 2019; 144-145:1-6. [PMID: 31279645 DOI: 10.1016/j.zefq.2019.05.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/19/2018] [Revised: 05/24/2019] [Accepted: 05/31/2019] [Indexed: 06/09/2023]
Abstract
OBJECTIVE In hospitals, case management (CM) on hospital wards is essential for maintaining a high level of quality and efficiency of care. The present study examined how CM at the Point of Care (POC) can be optimized and which potentials exist. METHODS The potentials for optimization of typical case management processes performed on hospital wards were analyzed using a structured interview guide. For this purpose, a field study was performed in 24 German hospital departments of tertiary care. Structured interviews were conducted with homogeneous focus groups. The results were evaluated using an extended Balanced Score Card approach and discussed afterwards with the focus groups. RESULTS Above all, the process quality and safety of case management as well as ensuring the relevant documentation at the POC appears to offer significant potential for optimization. An essential approach to eventually realize the potential for optimization is the reduction of fragmentation of the micro-processes associated with the case management duties on inpatient wards. This homogenization of these activities ideally requires a new and interdisciplinary acting profession, the clinical case managers. CONCLUSION The homogenization of the case management activities on hospital wards by clinical case managers has the potential and possibilities to relieve both medical and nursing staff of these activities, while improving the quality and efficiency of care for patients, staff and cross-sectoral healthcare provider at the same time.
Collapse
Affiliation(s)
- Martin Holderried
- Zentralbereich Medizin: Struktur-, Prozess- und Qualitätsmanagement, Universitätsklinikum Tübingen, Tübingen, Deutschland.
| | - Susanne Tenk
- Zentralbereich Medizin: Struktur-, Prozess- und Qualitätsmanagement, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - Hans-Peter Zenner
- Universitätsklinik für Hals-, Nasen- und Ohrenheilkunde mit Poliklinik, Tübingen, Deutschland
| | - Christian Ernst
- Institut für Health Care and Public Management, Universität Hohenheim, Stuttgart, Deutschland
| | - Helene Häberle
- Universitätsklinik für Anästhesiologie und Intensivmedizin, Tübingen, Deutschland
| | | |
Collapse
|
4
|
Reimann K, Schraven S, Dalhoff E, Zenner HP, Arnold H. Implantability of endaurally insertable active vibratory middle-ear implants - an anatomical study. Acta Otolaryngol 2019; 139:561-566. [PMID: 31112056 DOI: 10.1080/00016489.2019.1607974] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Background: Hearing loss is often treated with an acoustic hearing aid. However, distortion and insufficient gain may cause problems. Active non-acoustic vibratory middle-ear implants (AMEI) may contribute to solve this problem. We recently developed an AMEI which is to be implanted completely through the patient's external auditory canal. The device uses a light-emitting diode (LED) in the external auditory canal that stimulates a photovoltaic sensor, placed in the middle ear, through the intact tympanic membrane. This results in activation of a vibratory miniaturized piezoelectric displacement transducer (MDT) (actuator) coupled to the auditory organ. Aims/objectives: The aim of this study was to evaluate the anatomical implantability of the novel AMEI using an exclusively endaural approach. Materials and methods: The internal components of our AMEI were implanted into 39 human temporal bones. The surgical procedure and the optimal size and anatomical fitting were systematically evaluated. Results: We can show here that implantation of all components of this novel AMEI into anatomical specimens proves to be a quick and easy procedure, performed using an endaural approach. Conclusions and significance: The anatomical data of this study establish the basis for further technical development of our AMEI and other future implantable hearing systems.
Collapse
Affiliation(s)
- Katrin Reimann
- Department of Otorhinolaryngology, Head and Neck Surgery, Eberhard Karls University, Tübingen, Tübingen, Germany
- Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital of Marburg, Philipps-Universität Marburg, Marburg, Germany
| | - Sebastian Schraven
- Department of Otorhinolaryngology, Head and Neck Surgery “Otto Koerner”, Rostock University Medical Center, Rostock, Germany
| | - Erich Dalhoff
- Department of Otolaryngology, Section of Physiological Acoustics and Communication, University of Tübingen, Tübingen, Germany
| | - Hans-Peter Zenner
- Department of Otorhinolaryngology, Head and Neck Surgery, Eberhard Karls University, Tübingen, Tübingen, Germany
| | - Heinz Arnold
- Department of Otorhinolaryngology, Head and Neck Surgery, Eberhard Karls University, Tübingen, Tübingen, Germany
- Department of Otorhinolaryngology, Head and Neck Surgery, Ruhr University Bochum, St. Elisabeth-Hospital, Bochum
| |
Collapse
|
5
|
Beier HM, Bujard M, Diedrich K, Dreier H, Frister H, Kentenich H, Kreß H, Krüssel JS, Ludwig AK, Schumann E, Strowitzki T, Taupitz J, Thaler CJ, Thorn P, Wiesemann C, Zenner HP. Ein Fortpflanzungsmedizingesetz für Deutschland. Gynäkologische Endokrinologie 2018. [DOI: 10.1007/s10304-017-0173-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
6
|
Beier HM, Bujard M, Diedrich K, Dreier H, Frister H, Kentenich H, Kreß H, Krüssel JS, Ludwig AK, Schumann E, Strowitzki T, Taupitz J, Thaler CJ, Thorn P, Wiesemann C, Zenner HP. Ein Fortpflanzungsmedizingesetz für Deutschland. Ethik Med 2018. [DOI: 10.1007/s00481-017-0467-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
7
|
Zenner HP, Delb W, Kröner-Herwig B, Jäger B, Peroz I, Hesse G, Mazurek B, Goebel G, Gerloff C, Trollmann R, Biesinger E, Seidler H, Langguth B. A multidisciplinary systematic review of the treatment for chronic idiopathic tinnitus. Eur Arch Otorhinolaryngol 2016; 274:2079-2091. [DOI: 10.1007/s00405-016-4401-y] [Citation(s) in RCA: 93] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2016] [Accepted: 11/19/2016] [Indexed: 01/17/2023]
|
8
|
Zenner HP, Pfister M, Friese N, Zrenner E, Röcken M. [Personalized molecular medicine: new paradigms in the treatment of cochlear implant and cancer patients]. HNO 2014; 62:520-4. [PMID: 24920503 DOI: 10.1007/s00106-014-2859-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
OBJECTIVES To evaluate present options for the indication of cochlear implants (CI) and new forms of treatment for head and neck cancer, melanomas and basal cell carcinomas, with emphasis on future perspectives. METHODS A literature search was performed in the PubMed database. Search parameters were "personalized medicine", "individualized medicine" and "molecular medicine". RESULTS Personalized medicine based on molecular-genetic evaluation of functional proteins such as otoferlin, connexin 26 and KCNQ4 or the Usher gene is becoming increasingly important for the indication of CI in the context of infant deafness. Determination of HER2/EGFR mutations in the epithelial growth factor receptor (EGFR) gene may be an important prognostic parameter for therapeutic decisions in head and neck cancer patients. In basal cell carcinoma therapy, mutations in the Hedgehog (PCTH1) and Smoothened (SMO) pathways strongly influence the indication of therapeutic Hedgehog inhibition, e.g. using small molecules. Analyses of c-Kit receptor, BRAF-600E and NRAS mutations are required for specific molecular therapy of metastasizing melanomas. The significant advances in the field of specific molecular therapy are best illustrated by the availability of the first gene therapeutic procedures for treatment of RPE65-induced infantile retinal degradation. CONCLUSION The aim of personalized molecular medicine is to identify patients who will respond particularly positively or negatively (e.g. in terms of adverse side effects) to a therapy using the methods of molecular medicine. This should allow a specific therapy to be successfully applied or preclude its indication in order to avoid serious adverse side effects. This approach serves to stratify patients for adequate treatment.
Collapse
Affiliation(s)
- H P Zenner
- Universitätsklinik für HNO-Heilkunde, Universität Tübingen, Elfriede-Aulhorn-Str. 5, 72076, Tübingen, Deutschland,
| | | | | | | | | |
Collapse
|
9
|
Zenner HP, Vonthein R, Zenner B, Leuchtweis R, Plontke SK, Torka W, Pogge S, Birbaumer N. Standardized tinnitus-specific individual cognitive-behavioral therapy: A controlled outcome study with 286 tinnitus patients. Hear Res 2013; 298:117-25. [DOI: 10.1016/j.heares.2012.11.013] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/13/2011] [Revised: 10/13/2012] [Accepted: 11/12/2012] [Indexed: 11/25/2022]
|
10
|
Schraven SP, Hirt B, Goll E, Heyd A, Gummer AW, Zenner HP, Dalhoff E. Conditions for Highly Efficient and Reproducible Round-Window Stimulation in Humans. ACTA ACUST UNITED AC 2012; 17:133-8. [DOI: 10.1159/000333807] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2011] [Accepted: 09/22/2011] [Indexed: 11/19/2022]
|
11
|
Zenner HP. [Alternative treatment methods in otorhinolaryngology]. HNO 2011; 59:1158-9. [PMID: 22159334 DOI: 10.1007/s00106-011-2337-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
Affiliation(s)
- H P Zenner
- Universitäts-Hals-Nasen-Ohren-Klinik, Tübingen, Deutschland.
| |
Collapse
|
12
|
|
13
|
Schraven SP, Hirt B, Gummer AW, Zenner HP, Dalhoff E. Controlled round-window stimulation in human temporal bones yielding reproducible and functionally relevant stapedial responses. Hear Res 2011; 282:272-82. [PMID: 21798325 DOI: 10.1016/j.heares.2011.07.001] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/23/2011] [Revised: 07/04/2011] [Accepted: 07/06/2011] [Indexed: 10/17/2022]
Abstract
Stimulation of the round window (RW) has gained increasing clinical importance. Clinical, as well as human temporal bone and in-vivo animal studies show considerable variability. The influence of RW stimulation on the cochlea remains unclear. We designed a human temporal-bone study with controlled direct mechanical stimulation of the RW membrane to identify conditions for successful RW stimulation. Eight human temporal bones were stimulated on the RW by piezoelectric stack actuators with cylindrical aluminium rods of diameter 0.5 mm and with either flat or 30° inclined top surface. Using a dedicated two-stage positioning protocol for the actuator, we achieved highly reproducible measurements of the stimulus vibration at the RW and of the resultant vibration of the stapes footplate. The reverse transmission, characterized by the displacement ratio of the stapes-footplate relative to the actuator tip on the RW membrane, yielded an average displacement ratio of 0.089 up to 1.2 kHz when the actuator was coupled without angular misalignment to the RW membrane. The results suggest that 90-μm pretension of the RW membrane is essential for optimum and reproducible RW stimulation. The displacements are shown to be roughly consistent with the equal-volume displacement hypothesis under specific assumptions about the displacement mode of the RW membrane. It is further suggested that the large inter-patient variability in the effectiveness of RW stimulation might be due primarily to the success of coupling, rather than to the variability of functionally relevant anatomical parameters.
Collapse
Affiliation(s)
- Sebastian P Schraven
- University of Tübingen, Department of Otolaryngology, Tübingen Hearing Research Centre, Section of Physiological Acoustics and Communication, Elfriede-Aulhorn-Straße 5, D-72076 Tübingen, Germany.
| | | | | | | | | |
Collapse
|
14
|
Zenner HP, Rodriguez Jorge J. Totally implantable active middle ear implants: ten years' experience at the University of Tübingen. Adv Otorhinolaryngol 2010; 69:72-84. [PMID: 20610916 DOI: 10.1159/000318524] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Active middle ear implants do not produce acoustic sounds but, rather, micromechanical vibrations. The stimulating signal does not leave the transducer as sound, but as a mechanical vibration, directly coupled to the auditory system and bypassing the normal route via air. In this paper, we review our experience with the TICA and the Carina middle ear implants. Both are totally implantable and are coupled to the ossicular chain or to perilymph. The design requirements for electronic hearing implants for patients with conductive hearing loss differ from those for sensorineural hearing loss. Conductive hearing loss requires an implant that replaces impedance transformation and acts as an impedance transforming implant (ITI). In many respects, there are fewer demands on an ITI than on an electronic hearing aid for patients with sensorineural hearing loss.
Collapse
|
15
|
Dalhoff E, Turcanu D, Zenner HP, Gummer AW. Differential diagnosis using forward- and reverse-transfer functions: Measurements and models. Hear Res 2010. [DOI: 10.1016/j.heares.2010.03.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
16
|
Lauxmann M, Zenner HP, Jorge JR, Eiber A. Nonlinear stiffness characteristics of the ossicular chain. Hear Res 2010. [DOI: 10.1016/j.heares.2010.03.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
17
|
Plontke SK, Löwenheim H, Koitschev A, Zenner HP. Response toRandomized, Double Blind, Placebo Controlled Trial on the Safety and Efficacy of Continuous Intratympanic Dexamethasone Delivered Via a Round Window Catheter for Severe to Profound Sudden Idiopathic Sensorineural Hearing Loss After Failure of Systemic Therapy(Laryngoscope119:359â369, 2009). Laryngoscope 2009. [DOI: 10.1002/lary.20596] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
18
|
Plontke SK, Löwenheim H, Mertens J, Engel C, Meisner C, Weidner A, Zimmermann R, Preyer S, Koitschev A, Zenner HP. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope 2009; 119:359-69. [PMID: 19172627 DOI: 10.1002/lary.20074] [Citation(s) in RCA: 111] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
OBJECTIVES To study the safety and efficacy of continuous intratympanic dexamethasone-phosphate (Dex-P) for severe to profound sudden idiopathic sensorineural hearing (ISSHL) or sudden idiopathic anacusis after failure of systemic therapy. STUDY DESIGN Randomized, double-blind, placebo controlled multicenter trial. METHODS Patients with ISSHL and insufficient recovery (mean 4PTA = 97 dB HL) after systemic high dose glucocorticoid therapy received either Dex-P (4 mg/ml) or placebo (NaCl 0.9%) continuously applied for 14 days into the round window niche via a temporarily implanted catheter. For ethical reasons, intratympanic treatment was continued with Dex-P in all patients for another 14 days after the placebo-controlled study period. According to a two-step adaptive study design an interim analysis was performed after inclusion of 23 patients. RESULTS Intention-to-treat analysis for the primary outcome criterion (4PTA: 0.5-3 kHz) during the placebo controlled study period (14 days) showed an average hearing improvement in the treatment group of 13.9 dB (SD: 21.3) and in the placebo group of 5.4 dB (SD: 10.4). This difference in hearing improvement between the two groups (mean: 8.4 dB, SD: 17.0, 95% CI: -7.1-24.1) was statistically not significant (p = .26). Of the secondary outcome parameters, the largest benefit of local salvage therapy was found for maximum speech discrimination with an improvement of 24.4% (SD: 32.0) in the treatment and 4.5% (SD: 7.6) in the placebo group (p = 0.07). After a 3 month follow-up period (i.e. after all patients received intratympanic Dex-P) hearing improvement in the two groups was very similar. No serious adverse events were observed. Sample size calculation after the interim analysis resulted in stopping of the trial. CONCLUSIONS The tendency toward better hearing improvement in the treatment group, the rather conservative inclusion criteria, the limited placebo-controlled observation period and the absence of serious adverse events supports further investigation local inner ear drug delivery as a first or second line treatment option for ISSHL.
Collapse
Affiliation(s)
- Stefan K Plontke
- Department of Otorhinolaryngology, Head and Neck Surgery, University of Tübingen, Tübingen, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Turcanu D, Dalhoff E, Müller M, Zenner HP, Gummer AW. Accuracy of velocity distortion product otoacoustic emissions for estimating mechanically based hearing loss. Hear Res 2009; 251:17-28. [PMID: 19233253 DOI: 10.1016/j.heares.2009.02.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/18/2008] [Revised: 02/02/2009] [Accepted: 02/02/2009] [Indexed: 10/21/2022]
Abstract
Distortion product otoacoustic emissions (DPOAEs) measured as vibration of the human eardrum have been successfully used to estimate hearing threshold. The estimates have proved more accurate than similar methods using sound-pressure DPOAEs. Nevertheless, the estimation accuracy of the new technique might have been influenced by endogenous noise, such as heart beat, breathing and swallowing. Here, we investigate in an animal model to what extent the accuracy of the threshold estimation technique using velocity-DPOAEs might be improved by reducing noise sources. Velocity-DPOAE I/O functions were measured in normal and hearing-impaired anaesthetized guinea pigs. Hearing loss was either conductive or induced by furosemide injection. The estimated distortion product threshold (EDPT) obtained by extrapolation of the I/O function to the abscissa was found to linearly correlate with the compound action potential threshold at the f(2) frequency, provided that furosemide data were excluded. The standard deviation of the linear regression fit was 6 dB as opposed to 8 dB in humans, suggesting that this accuracy should be achievable in humans with appropriate improvement of signal-to-noise ratio. For the furosemide animals, the CAP threshold relative to the regression line provided an estimate of the functional loss of the inner hair cell system. For mechanical losses in the middle ear and/or cochlear amplifier, DPOAEs measured as velocity of the umbo promise an accuracy of hearing threshold estimation comparable to classical audiometry.
Collapse
Affiliation(s)
- Diana Turcanu
- Eberhard-Karls-University Tübingen, Department Otolaryngology, Section of Physiological Acoustics and Communication, Elfriede-Aulhorn-Strasse 5, Tübingen 72076, Germany.
| | | | | | | | | |
Collapse
|
20
|
Plontke SK, Zimmermann R, Zenner HP, Löwenheim H. Technical note on microcatheter implantation for local inner ear drug delivery: surgical technique and safety aspects. Otol Neurotol 2008; 27:912-7. [PMID: 17006340 DOI: 10.1097/01.mao.0000235310.72442.4e] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
HYPOTHESIS Despite its invasiveness, the temporary implantation of a microcatheter into the middle ear cavity is an appropriately safe method for providing continuous drug delivery to the inner ear. BACKGROUND For the application of drugs to the inner ear, different delivery strategies are available ranging from intratympanic injections to temporarily implanted microcatheters. It has recently been demonstrated that the choice of the drug delivery system influences the pharmacokinetics in the inner ear. If a continuous drug application over several weeks is required, a secure placement of the delivery device (i.e., the microcatheter) is necessary to guarantee efficient drug delivery and to avoid unwanted side effects. STUDY DESIGN Retrospective chart review. MATERIALS AND METHODS During 2000 to 2005, 25 patients with acute unilateral severe-to-profound hearing loss or anacusis and failure of systemic high-dose glucocorticoid and rheological therapy were offered an intratympanic delivery of glucocorticoids via a temporarily implanted catheter and an external pump for up to 4 weeks as a salvage treatment option. The standardized surgical implantation and fixation technique developed for the microcatheter were characterized by six elements: 1) a medial and a lateral tunnel connected by a groove in the posterior wall of the bony ear canal, 2) stabilization of the catheter with bone wax and soft tissue plugs in the tunnels, 3) an ear canal packing, 4) a series of fixating sutures along the catheter, 5) an adhesive dressing, and 6) additional tapes at the connecting line between pump and catheter. At the end of the implantation period, the catheter was removed by a second surgical procedure allowing for evaluation of the catheter position and the condition of the middle ear space. RESULTS Adverse events included catheter dislocation, catheter obstruction, formation of mild granulation tissue in the middle ear cavity, tympanic membrane defects, and ear canal skin defects. With introduction of an improved implantation and fixation technique, the number of catheter dislocations could be significantly reduced. No complications were observed on long-term follow-up. CONCLUSION If the pharmacokinetics or pharmacodynamics of a specific local inner ear therapy approach requires a continuous intratympanic drug application (e.g., to restore hearing in patients with severe or profound hearing loss), the temporary implantation of a microcatheter by a standardized surgical technique is a feasible and appropriately safe method for providing continuous drug delivery to the inner ear.
Collapse
Affiliation(s)
- Stefan K Plontke
- Department of Otorhinolaryngology, Head and Neck Surgery and Tübingen Hearing Research Center, University of Tübingen, Germany.
| | | | | | | |
Collapse
|
21
|
Wagner W, Frey K, Heppelmann G, Plontke SK, Zenner HP. Speech-in-noise intelligibility does not correlate with efferent olivocochlear reflex in humans with normal hearing. Acta Otolaryngol 2008; 128:53-60. [PMID: 17851961 DOI: 10.1080/00016480701361954] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
CONCLUSION According to the presented data, speech-in-noise intelligibility (SI) does not correlate with olivocochlear efferent activity - as measured by contralateral suppression (CS) of distortion product otoacoustic emissions (DPOAE) in humans with normal auditory threshold. OBJECTIVES Literature data indicate a possible role of the medial olivocochlear efferents in speech intelligibility, especially in background noise. The objective of this study was to investigate this relationship. MATERIALS AND METHODS SI was evaluated in three independent sessions by determining the ratio speech level/noise level, at which 50% of the words are understood (i.e. speech reception threshold, SRT). Efferent activity was inferred measuring CS of DPOAE, using two different paradigms with extensive variation of stimulus parameters and duplicate measurements. RESULTS For optimum measurement of CS, the study was restricted to subjects (n =49) with valid DPOAE down to primary tone levels L1=47/L2 =20 dB SPL. Average SRT was -6.66 dB (-4.50 to -7.65 dB, SD 0.63 dB). CS increased with decreasing primary tone levels, with mean absolute CS values in the range of 0.6-6 dB SPL. Test-retest repeatability was good. Statistical evaluation revealed no significant relationship between SI and CS of DPOAE.
Collapse
Affiliation(s)
- Wolfgang Wagner
- Tübingen Hearing Research Center, Department of Otolaryngology/Head and Neck Surgery, University of Tübingen, Germany.
| | | | | | | | | |
Collapse
|
22
|
Abstract
Nitric oxide (NO) production during hyposmotic stimulation in outer hair cells (OHCs) of the guinea pig cochlea was investigated using the NO sensitive dye DAF-2. Simultaneous measurement of the cell length and NO production showed rapid hyposmotic-induced cell swelling to precede NO production in OHCs. Hyposmotic stimulation failed to induce NO production in the Ca2+-free solution. L-NG-nitroarginine methyl ester (L-NAME), a non-specific NO synthase inhibitor and gadolinium, a stretch-activated channel blocker inhibited the hyposmotic stimulation-induced NO production whereas suramin, a P2 receptor antagonist did not. S-nitroso-N-acetylpenicillamine (SNAP), a NO donor inhibited the hyposmotic stimulation-induced increase in the intracellular Ca2+ concentrations ([Ca2+]i) while L-NAME enhanced it. 1H-[1,2,4]oxadiazole[4,3a]quinoxalin-1-one, an inhibitor of guanylate cyclase and KT5823, an inhibitor of cGMP-dependent protein kinase (PKG) mimicked effects of L-NAME on the Ca2+ response. Transient receptor potential vanilloid 4 (TRPV4), an osmo- and mechanosensitive channel was expressed in the OHCs by means of immunohistochemistry. 4alpha-phorbol 12,13-didecanoate, a TRPV4 synthetic activator, induced NO production in OHCs. These results suggest that hyposmotic stimulation can induce NO production by the [Ca2+]i increase, which is presumably mediated by the activation of TRPV4 in OHCs. NO conversely inhibits the Ca2+ response via the NO-cGMP-PKG pathway by a feedback mechanism.
Collapse
Affiliation(s)
- Hiroko Takeda-Nakazawa
- Hearing Research Laboratory, Department of Otolaryngology, Kansai Medical University, Fumizonocho 10-15, Moriguchi, Osaka 570-8507, Japan
| | | | | | | | | | | |
Collapse
|
23
|
Zenner HP, Holderried M. Wait-and-See-Antibiotikatherapie bei akuter Otitis media. HNO 2007; 55:156-7. [PMID: 17333047 DOI: 10.1007/s00106-006-1525-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- H P Zenner
- Universitäts-HNO-Klinik, 72076, Tübingen.
| | | |
Collapse
|
24
|
Abstract
Morbus Osler or HHT (hereditary hemorrhagic telangiectasia) is a disorder of the fibrovascular tissue that is inherited in an autosomal dominant way with frequency rates between 1:2,500 and 1:40,000. The disease provokes malformations of the blood vessels sometimes resulting in life-threatening complications. Presently, two genes involved in the development of HHT have been identified: ACVRL1 and ENG. Both of them encode proteins that belong to the TGF-beta receptor complex family and play an essential role in the formation of the vascular system. Recently, several mutations in ACVRL1 and ENG have been described in other European populations. However, no data concerning mutation frequencies in the German population have been reported so far. Therefore, we screened our collective of German HHT patients (28 single cases and 11 familial cases) for mutations in both genes by direct sequencing. We detected 11 mutations already described elsewhere and 19 novel ones. Furthermore, evidence for the pathogenic role of four new missense mutations was collected by screening a healthy control collective using RFLP analysis. Interestingly, the majority of ACVRL1 mutations represented missense mutations, whereas mutations in ENG mostly resulted in a shortened protein. Our results demonstrate the importance of ACVRL1 and ENG mutations in German HHT patients displaying mutation frequencies over 80%.
Collapse
Affiliation(s)
- Claudia Schulte
- Department of Otolaryngology, University of Tübingen, Tübingen, Germany
| | | | | | | | | | | | | |
Collapse
|
25
|
Haack B, Schmalisch K, Palmada M, Böhmer C, Kohlschmidt N, Keilmann A, Zechner U, Limberger A, Beckert S, Zenner HP, Lang F, Kupka S. Deficient membrane integration of the novel p.N14D-GJB2 mutant associated with non-syndromic hearing impairment. Hum Mutat 2006; 27:1158-9. [PMID: 17041897 DOI: 10.1002/humu.9464] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Mutations in GJB2, the gene encoding for the Gap Junction protein Connexin 26 (Cx26), have been established as the major cause of hereditary, non-syndromic hearing impairment (HI). We report here the identification of a novel point mutation in GJB2, c.40A>G [p.N14D], detected in compound heterozygosity with the c.35delG mutation in two brothers with moderate non-syndromic sensorineural HI. The mother who carried one wildtype and a p.N14D allele displayed normal hearing. The mutation leads to substitution of the neutral amino acid asparagine (N) by the negatively charged aspartic acid (D) at amino acid number 14, a position that is conserved among Cx26 of different organisms and among many other connexin isoforms. To investigate the impact of this mutation on protein function, Cx26 activity was measured by depolarization activated hemichannel conductance in non-coupled Xenopus laevis oocytes. Oocytes injected with the p.N14D mutant cRNA showed strongly reduced currents compared to wildtype. Coinjection of wildtype and mutant cRNA at equimolar levels restored the conductive properties supporting the recessive character of this mutation. Total Cx26 protein expression and cell surface abundance examined by western blotting and by quantitative immunoassays revealed that the hemichannel was properly synthesized but not integrated into the plasma membrane. In this study we have shown that the GJB2 mutation p.N14D is associated with recessively inherited HI and exhibits a defective phenotype due to diminished expression at the cell surface.
Collapse
Affiliation(s)
- B Haack
- Department of Molecular Pathology, University Hospital of Tübingen, Germany.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Plontke SK, Siedow N, Wegener R, Zenner HP, Salt AN. Cochlear pharmacokinetics with local inner ear drug delivery using a three-dimensional finite-element computer model. Audiol Neurootol 2006; 12:37-48. [PMID: 17119332 PMCID: PMC1779502 DOI: 10.1159/000097246] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2005] [Accepted: 08/02/2006] [Indexed: 11/19/2022] Open
Abstract
HYPOTHESIS Cochlear fluid pharmacokinetics can be better represented by three-dimensional (3D) finite-element simulations of drug dispersal. BACKGROUND Local drug deliveries to the round window membrane are increasingly being used to treat inner ear disorders. Crucial to the development of safe therapies is knowledge of drug distribution in the inner ear with different delivery methods. Computer simulations allow application protocols and drug delivery systems to be evaluated, and may permit animal studies to be extrapolated to the larger cochlea of the human. METHODS A finite-element 3D model of the cochlea was constructed based on geometric dimensions of the guinea pig cochlea. Drug propagation along and between compartments was described by passive diffusion. To demonstrate the potential value of the model, methylprednisolone distribution in the cochlea was calculated for two clinically relevant application protocols using pharmacokinetic parameters derived from a prior one-dimensional (1D) model. In addition, a simplified geometry was used to compare results from 3D with 1D simulations. RESULTS For the simplified geometry, calculated concentration profiles with distance were in excellent agreement between the 1D and the 3D models. Different drug delivery strategies produce very different concentration time courses, peak concentrations and basal-apical concentration gradients of drug. In addition, 3D computations demonstrate the existence of substantial gradients across the scalae in the basal turn. CONCLUSION The 3D model clearly shows the presence of drug gradients across the basal scalae of guinea pigs, demonstrating the necessity of a 3D approach to predict drug movements across and between scalae with larger cross-sectional areas, such as the human, with accuracy. This is the first model to incorporate the volume of the spiral ligament and to calculate diffusion through this structure. Further development of the 3D model will have to incorporate a more accurate geometry of the entire inner ear and incorporate more of the specific processes that contribute to drug removal from the inner ear fluids. Appropriate computer models may assist in both drug and drug delivery system design and can thus accelerate the development of a rationale-based local drug delivery to the inner ear and its successful establishment in clinical practice.
Collapse
Affiliation(s)
- Stefan K Plontke
- Department of Otorhinolaryngology, Head and Neck Surgery, Tübingen Hearing Research Center (THRC), University of Tübingen, Tübingen, Germany.
| | | | | | | | | |
Collapse
|
27
|
Takeda-Nakazawa H, Harada N, Shen J, Kubo N, Zenner HP, Yamashita T. Hyposmotic stimulation-induced nitric oxide production in outer hair cells of the guinea pig cochlea. Hear Res 2006; 227:59-70. [PMID: 17092670 DOI: 10.1016/j.heares.2006.09.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/21/2006] [Revised: 05/06/2006] [Accepted: 09/24/2006] [Indexed: 10/23/2022]
Abstract
Nitric oxide (NO) production during hyposmotic stimulation in outer hair cells (OHCs) of the guinea pig cochlea was investigated using the NO sensitive dye DAF-2. Simultaneous measurement of the cell length and NO production showed rapid hyposmotic-induced cell swelling to precede NO production in OHCs. Hyposmotic stimulation failed to induce NO production in the Ca(2+)-free solution. L-N(G)-nitroarginine methyl ester (L-NAME), a non-specific NO synthase inhibitor and gadolinium, a stretch-activated channel blocker inhibited the hyposmotic stimulation-induced NO production whereas suramin, a P2 receptor antagonist did not. S-nitroso-N-acetylpenicillamine (SNAP), a NO donor inhibited the hyposmotic stimulation-induced increase in the intracellular Ca(2+) concentrations ([Ca(2+)](i)) while L-NAME enhanced it. 1H-[1,2,4]oxadiazole[4,3a]quinoxalin-1-one, an inhibitor of guanylate cyclase and KT5823, an inhibitor of cGMP-dependent protein kinase (PKG) mimicked effects of L-NAME on the Ca(2+) response. Transient receptor potential vanilloid 4 (TRPV4), an osmo- and mechanosensitive channel was expressed in the OHCs by means of immunohistochemistry. 4alpha-phorbol 12,13-didecanoate, a TRPV4 synthetic activator, induced NO production in OHCs. These results suggest that hyposmotic stimulation can induce NO production by the [Ca(2+)](i) increase, which is presumably mediated by the activation of TRPV4 in OHCs. NO conversely inhibits the Ca(2+) response via the NO-cGMP-PKG pathway by a feedback mechanism.
Collapse
Affiliation(s)
- Hiroko Takeda-Nakazawa
- Hearing Research Laboratory, Department of Otolaryngology, Kansai Medical University, Fumizonocho 10-15, Moriguchi, Osaka 570-8507, Japan
| | | | | | | | | | | |
Collapse
|
28
|
Maassen MM, Malthan D, Stallkamp J, Schäfer A, Dammann F, Schwaderer E, Zenner HP. Laserbasierte Qualitätssicherung für die robotergestützte Fräsabtragung an der Schädelbasis. HNO 2006; 54:105-11. [PMID: 15977039 DOI: 10.1007/s00106-005-1283-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND Implanting active hearing devices in the lateral base of the skull requires high-precision, secure fixation of the electromagnetic transducer and long-life anchorage using osteosynthetic fixation plates referred to as mountain brackets. Nonlinear distortion in the acoustic signal path and consecutive implant loosening can only be avoided by exact osseous milling to create the necessary cavity bed while avoiding excessive milling. Robot technology is ideal for high-precision milling. However, safety measures are necessary in order to prevent errors from occurring during the reduction process. Ideally, a robot should be guided by a navigation system. However, robotic systems so far available do not yet have an integrated global navigation system. MATERIALS AND METHODS We used an animal model under laboratory conditions to examine the extent to which the semiautomatic ROBIN assistant system developed could be expected to increase osseous milling accuracy before implanting active electronic hearing devices into the recipient tissue in the cranium. An existing prototype system for robot-assisted skull base surgery was equipped with laser sensors for geometric measurement of the operation site. The three-dimensional measurement data was compared with CT simulation data before, during, and after the robot-assisted operation. The experiments were conducted on test objects as well as on animal models. RESULTS Under ideal conditions, the operation site could be measured at a spatial resolution of better than 0.02 mm in each dimension. However, reflections and impurities in the operation site from bleeding and rinsing fluids did have a considerable effect on data collection, necessitating specialised registering procedures. Using an error-tolerant procedure specifically developed, the effective registering error could be kept under 0.3 mm. After milling, the resulting shape matched the intended form at an accuracy level of 0.8 mm. CONCLUSION The results show that robot systems can reach the accuracy required for reliable microsurgery on the cranial base. High-resolution laser-based geometric measurement of the operation site enables head registration without additional artificial landmarks. During the navigated operation, the procedure can be used to ensure that the resulting cavity matches the intended shape as determined in the preoperative planning phase. This will enable quantitative analysis of, and improvement in the quality of robot-assisted surgery in the future.
Collapse
Affiliation(s)
- M M Maassen
- Universitätsklinik für Hals-, Nasen- und Ohrenheilkunde, Tübingen.
| | | | | | | | | | | | | |
Collapse
|
29
|
Tóth T, Pfister M, Zenner HP, Sziklai I. Phenotypic characterization of a DFNA6 family showing progressive low-frequency sensorineural hearing impairment. Int J Pediatr Otorhinolaryngol 2006; 70:201-6. [PMID: 16043233 DOI: 10.1016/j.ijporl.2005.06.011] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/16/2005] [Accepted: 06/06/2005] [Indexed: 11/28/2022]
Abstract
Only three autosomal dominant hearing loss loci (DFNA1, DFNA6/14/38 and DFNA54) have been reported to be associated with predominantly low-frequency (<2kHz) sensorineural hearing impairment (LFSNHI). The DFNA6 locus was previously mapped to chromosome 4p16.3. It was showed that WFS1 is located in this region. This study presents a six-generation family from Hungary with nonsyndromic, post-lingual, bilateral, symmetric, progressive LFSNHI, that discloses positive linkage to the DFNA6 region. Eleven genetically affected family members have LFSNHI. The HI is started before the age of 25 years. The severity of HI varies from mild to moderate, related to age. Progression was mild but significant at all frequencies causing a flat type audiogram. High-resolution temporal bone CT scan showed normal external, middle and inner ear without any osseus malformations in the temporal bone. Studying genotype-phenotype correlations will enhance our understanding of normal and disturbed hearing process.
Collapse
Affiliation(s)
- Tímea Tóth
- Medical and Health Science Center, ORL Clinic, University of Debrecen, Hungary.
| | | | | | | |
Collapse
|
30
|
Plontke S, Löwenheim H, Preyer S, Leins P, Dietz K, Koitschev A, Zimmermann R, Zenner HP. Outcomes research analysis of continuous intratympanic glucocorticoid delivery in patients with acute severe to profound hearing loss: basis for planning randomized controlled trials. Acta Otolaryngol 2005; 125:830-9. [PMID: 16158529 DOI: 10.1080/00016480510037898] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
CONCLUSIONS The data presented herein form the basis for conducting randomized placebo-controlled clinical trials evaluating the safety and efficacy of salvage treatment in patients with idiopathic sudden severe sensorineural hearing loss (but not anacusis) refractory to initial systemic therapy. Comparison of different application protocols and drug delivery systems will allow assessment of the value of continuous versus intermittent intratympanic glucocorticoid drug delivery. OBJECTIVES To describe and critically evaluate the results of continuous intratympanic glucocorticoid delivery in patients with acute unilateral severe and profound sensorineural hearing loss refractory to initial systemic therapy and to compare the outcome with a historical control group. MATERIAL AND METHODS In a retrospective chart review, treatment results were analyzed in 23 patients with acute severe and profound hearing loss and failure of systemic standard therapy who received a continuous intratympanic delivery of glucocorticoids as a salvage treatment. Audiological results were compared within the local therapy group and with the results of an historical control group who did not receive salvage treatment. The study and control groups were matched with respect to hearing loss after initial systemic treatment failure. RESULTS The average pure-tone threshold after intratympanic salvage treatment showed a statistically significant improvement of 15 dB (95% CI 7-24 dB; p<0.001). After exclusion of patients with complete anacusis, i.e. a non-measurable hearing threshold, the local therapy group showed a significantly better improvement (mean 19 dB; 95% CI 6-32 dB) than the historical control group (mean 5 dB; 95% CI -2-11 dB; p<0.05).
Collapse
Affiliation(s)
- Stefan Plontke
- Department of Otorhinolaryngology--Head and Neck Surgery and Tübingen Hearing Research Center, University of Tübingen, Tübingen, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Löwenheim H, Reichl J, Winter H, Hahn H, Simon C, Gültig K, Müller A, Zenner HP, Zimmermann U, Knipper M. In vitro expansion of human nasoseptal chondrocytes reveals distinct expression profiles of G1 cell cycle inhibitors for replicative, quiescent, and senescent culture stages. ACTA ACUST UNITED AC 2005; 11:64-75. [PMID: 15738662 DOI: 10.1089/ten.2005.11.64] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
In vitro expansion of chondrocytes for tissue-engineering applications is limited by forms of growth arrest known as quiescence and replicative senescence. At the molecular level cyclin-dependent kinase inhibitors (CDKIs) are involved in mediating growth arrest in the G1 phase of the cell cycle. Using ribonuclease protection assays and immunocytochemical staining methods, we quantitatively analyzed expression profiles of G1 cell cycle inhibitors at the mRNA and protein levels. These inhibitors included the CDKIs of the CIP/KIP family (p21CIP1 p27KIP1, and p57KIP2) and the INK4 family (p15INK4b, p16INK4a, p18INK4c, and p19INK4d) as well as the retinoblastoma protein-family (pRb, p107, and p130) and the tumor suppressor p53. Analysis was carried out in proliferating, quiescent, and senescent states of primary cultures of adult human nasoseptal chondrocytes. The most pronounced effect (p < 0.0001) between cultures in proliferation and cultures in growth arrest was an increased expression of the CDKIs p57KIP2 and p15INK4b for quiescent growth arrest, and of p16INK4a, p15INK4b, and p57KIP2 for senescent growth arrest. Thus, these cell cycle inhibitors represent potential candidates for selective intervention to promote cellular multiplication of chondrocytes undergoing in vitro expansion for tissue-engineering applications. Possible methods of modulation include the targeted elimination of specifically identified cell cycle inhibitors by antisense technologies.
Collapse
Affiliation(s)
- Hubert Löwenheim
- Department of Otolaryngology-Head and Neck Surgery, Hearing Research Center Tübingen, University of Tübingen Medical Center, Tübingen, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Kupka S, Bodden-Kamps B, Baur M, Zenner HP, Pfister M. [Mitochondrial A1555G mutation. Molecular genetic diagnosis in sporadic cases of non-syndromic hearing impairment]. HNO 2005; 52:968-72. [PMID: 15309320 DOI: 10.1007/s00106-003-0994-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
BACKGROUND The A1555G mutation in mitochondrial DNA is the cause of hearing impairment in about 50% of all carriers. The severity and onset of this impairment is predominantly affected by the use of aminoglycosides. PATIENTS AND METHODS A total of 391 patients displaying sporadic, non-syndromic, mild to severe hearing impairment were analyzed for the A1555G mutation using molecular genetic methods. RESULTS We analysed additional family members of the two patients (0.5% of the total) who had the mutation. All maternal relatives carried the mutation, but only three individuals from the two families displayed a variable sensorineural hearing loss. CONCLUSION The A1555G mutation is infrequently involved as a genetic cause of sporadic, non-syndromic hearing impairment. Nevertheless, based on the variable clinical outcome of hearing impairment and the possibility of preventive steps, a genetic test in this patient subgroup is indicated.
Collapse
Affiliation(s)
- S Kupka
- Hals-Nasen-Ohren-Klinik der Universität Tübingen
| | | | | | | | | |
Collapse
|
33
|
Pfister M, Thiele H, Van Camp G, Fransen E, Apaydin F, Aydin O, Leistenschneider P, Devoto M, Zenner HP, Blin N, Nürnberg P, Ozkarakas H, Kupka S. A genotype-phenotype correlation with gender-effect for hearing impairment caused by TECTA mutations. Cell Physiol Biochem 2005; 14:369-76. [PMID: 15319541 DOI: 10.1159/000080347] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/16/2003] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Alpha-tectorin is a noncollagenous component of the tectorial membrane which plays an essential role in auditory transduction. In several DFNA12 families mutations in TECTA, the gene encoding alpha-tectorin, were shown to cause hearing impairment (HI) with different phenotypes depending on the location of the mutation. METHODS/RESULTS Here we report a Turkish family displaying autosomal dominant inherited HI. Linkage analysis revealed significant cosegregation (LOD score: 4.6) of the disease to markers on chromosome 11q23.3- q24. This region contains the TECTA gene which was subsequently sequenced. A nucleotide change in exon 13, 4526T>G, was detected leading to a substitution from cysteine to glycine at codon 1509 of the TECTA protein. This cysteine is located in vWFD4 domain, a protein domain which is supposed to be involved in disulfide bonds and protein-protein interactions. CONCLUSIONS It is conspicuous that the phenotype in this family correlates with other families, also displaying mutations involving conserved cysteines. In all three families these mutations result in progressive HI involving high frequencies. In contrast, mutations which are not affecting the vWFD domains seem to provoke mid-frequency sensorineural HI. Furthermore, evaluation of clinical data in our family revealed a gender effect for the severity of hearing impairment. Males were significantly more affected than females. The identification of the third family displaying a missense mutation in the vWFD domain of alpha-tectorin underlines the phenotype-genotype correlation based on different mutations in TECTA.
Collapse
Affiliation(s)
- Markus Pfister
- Department of Otolaryngology, University of Tübingen, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Tropitzsch A, Zenner HP. [Decontamination and sterilization of surgical instruments in suspected Creutzfeldt-Jakob disease. Are we converting to the recommendations by the Robert Koch Institute?]. HNO 2004; 52:871-4. [PMID: 15309323 DOI: 10.1007/s00106-004-1151-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
35
|
Zenner HP, Freitag HG, Linti C, Steinhardt U, Rodriguez Jorge J, Preyer S, Mauz PS, Sürth M, Planck H, Baumann I, Lehner R, Eiber A. Acoustomechanical properties of open TTP® titanium middle ear prostheses. Hear Res 2004; 192:36-46. [PMID: 15157961 DOI: 10.1016/j.heares.2004.02.004] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/30/2003] [Accepted: 02/13/2004] [Indexed: 10/26/2022]
Abstract
OBJECTIVE The purpose of the study was to identify acoustcomechanical properties of various biostable and biocompatible materials to create a middle ear prosthesis with the following properties: (i) improved handling including a good view of the head of the stapes or footplate and adjustable length, (ii) improved acoustical characteristics that are adequate for ossiculoplastic. The identified material should serve to build CE and FDA approved prostheses for clinical use in patients. METHODS Test models made of Teflon, polyetheretherketone, polyethylenterephtalate, polysulfone, gold, Al2O3 ceramics, carbon and titanium were investigated for their potential to fulfill the requirements. Acoustical properties were investigated by laser Doppler velocimetry (LDV) in mechanical middle ear models (MMM). Measured data were fed in to a recently created computer model of the middle ear (multibody systems approach, MBS). Using computer-aided design (CAD) measured and computed data allowed creation and fine precision of titanium prostheses (Tübingen Titanium Protheses, TTP). Their handling was tested in temporal bones. Acoustomechanical properties were investigated using the MBS and mechanical middle ear models. MAIN OUTCOME MEASURES Input impedance, mass, stiffness, and geometry of test models and prostheses were determined. Furthermore, their influence on the intraprosthetic transfer functions and on coupling to either tympanic membrane or stapes was investigated. RESULTS Final results were FDA- and CE-approved filigreed titanium prostheses with an open head that fulfilled the four requirements detailed above. The prostheses (TTP) were developed in defined lengths of between 1.75 and 3.5 mm (partial) and 3.0 and 6.5 mm (total) as well as in adjustable lengths (TTP-Vario). CONCLUSIONS The results suggest acoustomechanical advantages of TTPs because they combine a significantly low mass with high stiffness. In contrast to closed prostheses, the open head and filigreed design allow an excellent view of the prosthesis foot during coupling to the head or footplate of stapes, contributing to an improved intraoperative reliability of prosthesis coupling.
Collapse
Affiliation(s)
- H P Zenner
- Department of Otolaryngology, The University of Tübingen, Germany.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Tóth T, Kupka S, Haack B, Riemann K, Braun S, Fazakas F, Zenner HP, Muszbek L, Blin N, Pfister M, Sziklai I. GJB2mutations in patients with non-syndromic hearing loss from Northeastern Hungary. Hum Mutat 2004; 23:631-2. [PMID: 15146474 DOI: 10.1002/humu.9250] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Mutations in the GJB2 gene encoding the gap-junction protein connexin 26 have been identified in many patients with childhood hearing impairment (HI). One single mutation, c.35delG, accounts for the majority of mutations in Caucasian patients with HI. In the present study we screened 500 healthy control individuals and a group of patients with HI from Northeastern Hungary for GJB2 mutations. The patients' group consisted of 102 familial from 28 families and 92 non-familial cases. The most common mutation in the Hungarian population is the c.35delG, followed by the c.71G>A (p.W24X) mutation. 34.3% of the patients in the familial group were homozygous, and 17.6% heterozygous for 35delG. In the non-familial group the respective values were 37% and 18% (allele frequency: 46.2%). In the general population an allele frequency of 2.4% was determined. Several patients were identified with additional, already described or new GJB2 mutations, mostly in heterozygous state. The mutation c.380G>A (p.R127H) was formerly found only in heterozygous state and its disease relation was controversial. We demonstrated the presence of this mutation in a family with three homozygous patients and 4 heterozygous unaffected family members, a clear indication of recessively inherited HI. Furthermore, we provided evidence for the pathogenic role of two new mutations, c.51C>A (p.S17Y) and c.177G>T (p.G59V), detected in the present study. In the latter case the pattern of inheritance might be dominant. Our results confirm the importance of GJB2 mutations in the Hungarian population displaying mutation frequencies that are comparable with those in the Mediterranean area.
Collapse
Affiliation(s)
- Tímea Tóth
- Medical and Health Science Center, Department of Otolaryngology, University of Debrecen, Hungary
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Abstract
OBJECTIVE Acquired centralized tinnitus (ACT) is the most frequent type of chronic tinnitus. We introduce a cognitive neurophysiological ACT hypothesis based on centralized cognitive sensitization processes. MATERIAL AND METHODS Published cognitive sensitization processes were reviewed using PubMed. Furthermore, a Cochrane analysis was performed. RESULTS Patients frequently perceive tinnitus as being extremely loud although audiological tinnitus-matching measures reveal that its loudness levels are low. An important principle of central tinnitus processing is that individual tinnitus appraisal is directly linked to neuronal networks in the brain responsible for the production of emotions and cognitions. Cognitive processes may be associated with a reduction in the tinnitus cognition threshold, resulting in hypersensitivity of cognition. The underlying mechanism is known as sensitization and is suggested to be a specific learning process. CONCLUSIONS ACT may be associated with a specific learning process allowing increased tinnitus awareness and continuous appraisal. The underlying mechanism, the cognitive tinnitus sensitization process, is associated with a decrease in the tinnitus cognition threshold. The sensitization contributes to the extremely loud cognition of the tinnitus signal. The associated audiological cognitive discrepancy can be used clinically and diagnostically to identify patients for cognitive testing. The sensitization model does not require tinnitus hyperactivity.
Collapse
Affiliation(s)
- Hans-Peter Zenner
- Department of Otolaryngology, University of Tübingen, Tübingen, Germany.
| | | |
Collapse
|
38
|
Riemann K, Sotlar K, Kupka S, Braun S, Zenner HP, Preyer S, Pfister M, Pusch CM, Blin N. Chromosome 11 monosomy in conjunction with a mutated SDHD initiation codon in nonfamilial paraganglioma cases. ACTA ACUST UNITED AC 2004; 150:128-35. [PMID: 15066320 DOI: 10.1016/j.cancergencyto.2003.10.013] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2003] [Revised: 10/10/2003] [Accepted: 10/17/2003] [Indexed: 11/30/2022]
Abstract
Paragangliomas of the head and neck region are a group of rare, usually benign, slow-growing tumors developing from paraganglionic chemoreceptors in most patients. Mutations in a subunit of the mitochondrial enzyme II complex (succinate dehydrogenase [SDHD]) were shown to be responsible for the formation of paragangliomas. In addition, loss of heterozygosity (LOH) on chromosome 11, mainly in 11q23 (PGL1), was observed recently. We analyzed DNA derived from tumor sections of three unrelated paraganglioma patients (one case with multiple paragangliomas, two cases with single tumors; all of them sporadic cases) for mutations in the SDHD gene by direct sequencing. Microsatellite-based LOH was performed, and events of chromosomal loss were validated by fluorescence in situ hybridization (FISH) on paraffin-embedded tumor and normal tissue by using centromeric satellite DNA. Sequence analysis revealed mutations in SDHD exon 1 in all patients, affecting the initiation codon (M1V). Another alteration was detected in exon 2 but was lacking in tumor DNA and therefore classified as polymorphism (H50R). LOH and FISH analyses demonstrated partial/total monosomy for chromosome 11 in the tumor samples tested. A common genetic mechanism appears to be the pathophysiologic basis for sporadic tumor development because the proposed two-hit model comprising both LOH and point mutation is manifest in our patients. Loss of chromosome 11 regions, including the deletion of PGL1 and PGL2 loci, may result in a more severe phenotype, as exemplified by the development of multiple tumors in one of the patients.
Collapse
Affiliation(s)
- Kathrin Riemann
- Institute of Pathology, University of Tübingen, Wilhelmstrasse 27, 72074 Tübingen, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Donaudy F, Snoeckx R, Pfister M, Zenner HP, Blin N, Di Stazio M, Ferrara A, Lanzara C, Ficarella R, Declau F, Pusch CM, Nürnberg P, Melchionda S, Zelante L, Ballana E, Estivill X, Van Camp G, Gasparini P, Savoia A. Nonmuscle myosin heavy-chain gene MYH14 is expressed in cochlea and mutated in patients affected by autosomal dominant hearing impairment (DFNA4). Am J Hum Genet 2004; 74:770-6. [PMID: 15015131 PMCID: PMC1181955 DOI: 10.1086/383285] [Citation(s) in RCA: 120] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2003] [Accepted: 01/30/2004] [Indexed: 11/03/2022] Open
Abstract
Myosins have been implicated in various motile processes, including organelle translocation, ion-channel gating, and cytoskeleton reorganization. Different members of the myosin superfamily are responsible for syndromic and nonsyndromic hearing impairment in both humans and mice. MYH14 encodes one of the heavy chains of the class II nonmuscle myosins, and it is localized within the autosomal dominant hearing impairment (DFNA4) critical region. After demonstrating that MYH14 is highly expressed in mouse cochlea, we performed a mutational screening in a large series of 300 hearing-impaired patients from Italy, Spain, and Belgium and in a German kindred linked to DFNA4. This study allowed us to identify a nonsense and two missense mutations in large pedigrees, linked to DFNA4, as well as a de novo allele in a sporadic case. Absence of these mutations in healthy individuals was tested in 200 control individuals. These findings clearly demonstrate the role of MYH14 in causing autosomal dominant hearing loss and further confirm the crucial role of the myosin superfamily in auditive functions.
Collapse
Affiliation(s)
- Francesca Donaudy
- Telethon Institute of Genetics and Medicine and Genetica Medica, Dipartimento di Patologia Generale, Seconda Università di Napoli, Naples, Department of Medical Genetics, University of Antwerp, and Department of Otolaryngology, University Hospital, Antwerp; Department of Otolaryngology, University Hospital, and Institute of Anthropology and Human Genetics, Division of Molecular Genetics, University of Tübingen, Tübingen, Germany; Gene Mapping Center, Max Delbrueck Center for Molecular Medicine, and Institute of Medical Genetics, Charité, Humboldt University, Berlin; Servizio Genetica Medica, IRCCS-CSS, San Giovanni Rotondo, Foggia; and Center for Genomic Regulation, Pompeu Fabra University, Barcelona Biomedical Research Park, Barcelona
| | - Rik Snoeckx
- Telethon Institute of Genetics and Medicine and Genetica Medica, Dipartimento di Patologia Generale, Seconda Università di Napoli, Naples, Department of Medical Genetics, University of Antwerp, and Department of Otolaryngology, University Hospital, Antwerp; Department of Otolaryngology, University Hospital, and Institute of Anthropology and Human Genetics, Division of Molecular Genetics, University of Tübingen, Tübingen, Germany; Gene Mapping Center, Max Delbrueck Center for Molecular Medicine, and Institute of Medical Genetics, Charité, Humboldt University, Berlin; Servizio Genetica Medica, IRCCS-CSS, San Giovanni Rotondo, Foggia; and Center for Genomic Regulation, Pompeu Fabra University, Barcelona Biomedical Research Park, Barcelona
| | - Markus Pfister
- Telethon Institute of Genetics and Medicine and Genetica Medica, Dipartimento di Patologia Generale, Seconda Università di Napoli, Naples, Department of Medical Genetics, University of Antwerp, and Department of Otolaryngology, University Hospital, Antwerp; Department of Otolaryngology, University Hospital, and Institute of Anthropology and Human Genetics, Division of Molecular Genetics, University of Tübingen, Tübingen, Germany; Gene Mapping Center, Max Delbrueck Center for Molecular Medicine, and Institute of Medical Genetics, Charité, Humboldt University, Berlin; Servizio Genetica Medica, IRCCS-CSS, San Giovanni Rotondo, Foggia; and Center for Genomic Regulation, Pompeu Fabra University, Barcelona Biomedical Research Park, Barcelona
| | - Hans-Peter Zenner
- Telethon Institute of Genetics and Medicine and Genetica Medica, Dipartimento di Patologia Generale, Seconda Università di Napoli, Naples, Department of Medical Genetics, University of Antwerp, and Department of Otolaryngology, University Hospital, Antwerp; Department of Otolaryngology, University Hospital, and Institute of Anthropology and Human Genetics, Division of Molecular Genetics, University of Tübingen, Tübingen, Germany; Gene Mapping Center, Max Delbrueck Center for Molecular Medicine, and Institute of Medical Genetics, Charité, Humboldt University, Berlin; Servizio Genetica Medica, IRCCS-CSS, San Giovanni Rotondo, Foggia; and Center for Genomic Regulation, Pompeu Fabra University, Barcelona Biomedical Research Park, Barcelona
| | - Nikolaus Blin
- Telethon Institute of Genetics and Medicine and Genetica Medica, Dipartimento di Patologia Generale, Seconda Università di Napoli, Naples, Department of Medical Genetics, University of Antwerp, and Department of Otolaryngology, University Hospital, Antwerp; Department of Otolaryngology, University Hospital, and Institute of Anthropology and Human Genetics, Division of Molecular Genetics, University of Tübingen, Tübingen, Germany; Gene Mapping Center, Max Delbrueck Center for Molecular Medicine, and Institute of Medical Genetics, Charité, Humboldt University, Berlin; Servizio Genetica Medica, IRCCS-CSS, San Giovanni Rotondo, Foggia; and Center for Genomic Regulation, Pompeu Fabra University, Barcelona Biomedical Research Park, Barcelona
| | - Mariateresa Di Stazio
- Telethon Institute of Genetics and Medicine and Genetica Medica, Dipartimento di Patologia Generale, Seconda Università di Napoli, Naples, Department of Medical Genetics, University of Antwerp, and Department of Otolaryngology, University Hospital, Antwerp; Department of Otolaryngology, University Hospital, and Institute of Anthropology and Human Genetics, Division of Molecular Genetics, University of Tübingen, Tübingen, Germany; Gene Mapping Center, Max Delbrueck Center for Molecular Medicine, and Institute of Medical Genetics, Charité, Humboldt University, Berlin; Servizio Genetica Medica, IRCCS-CSS, San Giovanni Rotondo, Foggia; and Center for Genomic Regulation, Pompeu Fabra University, Barcelona Biomedical Research Park, Barcelona
| | - Antonella Ferrara
- Telethon Institute of Genetics and Medicine and Genetica Medica, Dipartimento di Patologia Generale, Seconda Università di Napoli, Naples, Department of Medical Genetics, University of Antwerp, and Department of Otolaryngology, University Hospital, Antwerp; Department of Otolaryngology, University Hospital, and Institute of Anthropology and Human Genetics, Division of Molecular Genetics, University of Tübingen, Tübingen, Germany; Gene Mapping Center, Max Delbrueck Center for Molecular Medicine, and Institute of Medical Genetics, Charité, Humboldt University, Berlin; Servizio Genetica Medica, IRCCS-CSS, San Giovanni Rotondo, Foggia; and Center for Genomic Regulation, Pompeu Fabra University, Barcelona Biomedical Research Park, Barcelona
| | - Carmen Lanzara
- Telethon Institute of Genetics and Medicine and Genetica Medica, Dipartimento di Patologia Generale, Seconda Università di Napoli, Naples, Department of Medical Genetics, University of Antwerp, and Department of Otolaryngology, University Hospital, Antwerp; Department of Otolaryngology, University Hospital, and Institute of Anthropology and Human Genetics, Division of Molecular Genetics, University of Tübingen, Tübingen, Germany; Gene Mapping Center, Max Delbrueck Center for Molecular Medicine, and Institute of Medical Genetics, Charité, Humboldt University, Berlin; Servizio Genetica Medica, IRCCS-CSS, San Giovanni Rotondo, Foggia; and Center for Genomic Regulation, Pompeu Fabra University, Barcelona Biomedical Research Park, Barcelona
| | - Romina Ficarella
- Telethon Institute of Genetics and Medicine and Genetica Medica, Dipartimento di Patologia Generale, Seconda Università di Napoli, Naples, Department of Medical Genetics, University of Antwerp, and Department of Otolaryngology, University Hospital, Antwerp; Department of Otolaryngology, University Hospital, and Institute of Anthropology and Human Genetics, Division of Molecular Genetics, University of Tübingen, Tübingen, Germany; Gene Mapping Center, Max Delbrueck Center for Molecular Medicine, and Institute of Medical Genetics, Charité, Humboldt University, Berlin; Servizio Genetica Medica, IRCCS-CSS, San Giovanni Rotondo, Foggia; and Center for Genomic Regulation, Pompeu Fabra University, Barcelona Biomedical Research Park, Barcelona
| | - Frank Declau
- Telethon Institute of Genetics and Medicine and Genetica Medica, Dipartimento di Patologia Generale, Seconda Università di Napoli, Naples, Department of Medical Genetics, University of Antwerp, and Department of Otolaryngology, University Hospital, Antwerp; Department of Otolaryngology, University Hospital, and Institute of Anthropology and Human Genetics, Division of Molecular Genetics, University of Tübingen, Tübingen, Germany; Gene Mapping Center, Max Delbrueck Center for Molecular Medicine, and Institute of Medical Genetics, Charité, Humboldt University, Berlin; Servizio Genetica Medica, IRCCS-CSS, San Giovanni Rotondo, Foggia; and Center for Genomic Regulation, Pompeu Fabra University, Barcelona Biomedical Research Park, Barcelona
| | - Carsten M. Pusch
- Telethon Institute of Genetics and Medicine and Genetica Medica, Dipartimento di Patologia Generale, Seconda Università di Napoli, Naples, Department of Medical Genetics, University of Antwerp, and Department of Otolaryngology, University Hospital, Antwerp; Department of Otolaryngology, University Hospital, and Institute of Anthropology and Human Genetics, Division of Molecular Genetics, University of Tübingen, Tübingen, Germany; Gene Mapping Center, Max Delbrueck Center for Molecular Medicine, and Institute of Medical Genetics, Charité, Humboldt University, Berlin; Servizio Genetica Medica, IRCCS-CSS, San Giovanni Rotondo, Foggia; and Center for Genomic Regulation, Pompeu Fabra University, Barcelona Biomedical Research Park, Barcelona
| | - Peter Nürnberg
- Telethon Institute of Genetics and Medicine and Genetica Medica, Dipartimento di Patologia Generale, Seconda Università di Napoli, Naples, Department of Medical Genetics, University of Antwerp, and Department of Otolaryngology, University Hospital, Antwerp; Department of Otolaryngology, University Hospital, and Institute of Anthropology and Human Genetics, Division of Molecular Genetics, University of Tübingen, Tübingen, Germany; Gene Mapping Center, Max Delbrueck Center for Molecular Medicine, and Institute of Medical Genetics, Charité, Humboldt University, Berlin; Servizio Genetica Medica, IRCCS-CSS, San Giovanni Rotondo, Foggia; and Center for Genomic Regulation, Pompeu Fabra University, Barcelona Biomedical Research Park, Barcelona
| | - Salvatore Melchionda
- Telethon Institute of Genetics and Medicine and Genetica Medica, Dipartimento di Patologia Generale, Seconda Università di Napoli, Naples, Department of Medical Genetics, University of Antwerp, and Department of Otolaryngology, University Hospital, Antwerp; Department of Otolaryngology, University Hospital, and Institute of Anthropology and Human Genetics, Division of Molecular Genetics, University of Tübingen, Tübingen, Germany; Gene Mapping Center, Max Delbrueck Center for Molecular Medicine, and Institute of Medical Genetics, Charité, Humboldt University, Berlin; Servizio Genetica Medica, IRCCS-CSS, San Giovanni Rotondo, Foggia; and Center for Genomic Regulation, Pompeu Fabra University, Barcelona Biomedical Research Park, Barcelona
| | - Leopoldo Zelante
- Telethon Institute of Genetics and Medicine and Genetica Medica, Dipartimento di Patologia Generale, Seconda Università di Napoli, Naples, Department of Medical Genetics, University of Antwerp, and Department of Otolaryngology, University Hospital, Antwerp; Department of Otolaryngology, University Hospital, and Institute of Anthropology and Human Genetics, Division of Molecular Genetics, University of Tübingen, Tübingen, Germany; Gene Mapping Center, Max Delbrueck Center for Molecular Medicine, and Institute of Medical Genetics, Charité, Humboldt University, Berlin; Servizio Genetica Medica, IRCCS-CSS, San Giovanni Rotondo, Foggia; and Center for Genomic Regulation, Pompeu Fabra University, Barcelona Biomedical Research Park, Barcelona
| | - Ester Ballana
- Telethon Institute of Genetics and Medicine and Genetica Medica, Dipartimento di Patologia Generale, Seconda Università di Napoli, Naples, Department of Medical Genetics, University of Antwerp, and Department of Otolaryngology, University Hospital, Antwerp; Department of Otolaryngology, University Hospital, and Institute of Anthropology and Human Genetics, Division of Molecular Genetics, University of Tübingen, Tübingen, Germany; Gene Mapping Center, Max Delbrueck Center for Molecular Medicine, and Institute of Medical Genetics, Charité, Humboldt University, Berlin; Servizio Genetica Medica, IRCCS-CSS, San Giovanni Rotondo, Foggia; and Center for Genomic Regulation, Pompeu Fabra University, Barcelona Biomedical Research Park, Barcelona
| | - Xavier Estivill
- Telethon Institute of Genetics and Medicine and Genetica Medica, Dipartimento di Patologia Generale, Seconda Università di Napoli, Naples, Department of Medical Genetics, University of Antwerp, and Department of Otolaryngology, University Hospital, Antwerp; Department of Otolaryngology, University Hospital, and Institute of Anthropology and Human Genetics, Division of Molecular Genetics, University of Tübingen, Tübingen, Germany; Gene Mapping Center, Max Delbrueck Center for Molecular Medicine, and Institute of Medical Genetics, Charité, Humboldt University, Berlin; Servizio Genetica Medica, IRCCS-CSS, San Giovanni Rotondo, Foggia; and Center for Genomic Regulation, Pompeu Fabra University, Barcelona Biomedical Research Park, Barcelona
| | - Guy Van Camp
- Telethon Institute of Genetics and Medicine and Genetica Medica, Dipartimento di Patologia Generale, Seconda Università di Napoli, Naples, Department of Medical Genetics, University of Antwerp, and Department of Otolaryngology, University Hospital, Antwerp; Department of Otolaryngology, University Hospital, and Institute of Anthropology and Human Genetics, Division of Molecular Genetics, University of Tübingen, Tübingen, Germany; Gene Mapping Center, Max Delbrueck Center for Molecular Medicine, and Institute of Medical Genetics, Charité, Humboldt University, Berlin; Servizio Genetica Medica, IRCCS-CSS, San Giovanni Rotondo, Foggia; and Center for Genomic Regulation, Pompeu Fabra University, Barcelona Biomedical Research Park, Barcelona
| | - Paolo Gasparini
- Telethon Institute of Genetics and Medicine and Genetica Medica, Dipartimento di Patologia Generale, Seconda Università di Napoli, Naples, Department of Medical Genetics, University of Antwerp, and Department of Otolaryngology, University Hospital, Antwerp; Department of Otolaryngology, University Hospital, and Institute of Anthropology and Human Genetics, Division of Molecular Genetics, University of Tübingen, Tübingen, Germany; Gene Mapping Center, Max Delbrueck Center for Molecular Medicine, and Institute of Medical Genetics, Charité, Humboldt University, Berlin; Servizio Genetica Medica, IRCCS-CSS, San Giovanni Rotondo, Foggia; and Center for Genomic Regulation, Pompeu Fabra University, Barcelona Biomedical Research Park, Barcelona
| | - Anna Savoia
- Telethon Institute of Genetics and Medicine and Genetica Medica, Dipartimento di Patologia Generale, Seconda Università di Napoli, Naples, Department of Medical Genetics, University of Antwerp, and Department of Otolaryngology, University Hospital, Antwerp; Department of Otolaryngology, University Hospital, and Institute of Anthropology and Human Genetics, Division of Molecular Genetics, University of Tübingen, Tübingen, Germany; Gene Mapping Center, Max Delbrueck Center for Molecular Medicine, and Institute of Medical Genetics, Charité, Humboldt University, Berlin; Servizio Genetica Medica, IRCCS-CSS, San Giovanni Rotondo, Foggia; and Center for Genomic Regulation, Pompeu Fabra University, Barcelona Biomedical Research Park, Barcelona
| |
Collapse
|
40
|
Plontke S, Löwenheim H, Preyer S, Leins P, Koitschev A, Zimmermann R, Zenner HP. Klinische Erfahrungen mit der lokalen Kortikosteroidapplikation in die Rundfensternische bei akuter, hochgradiger Hörminderung und akuter Ertaubung. Laryngorhinootologie 2004. [DOI: 10.1055/s-2004-823325] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
41
|
Hahn H, Kammerer B, DiMauro A, Plontke S, Zenner HP. Mikrodialyse für pharmakokinetische Untersuchungen im Innenohr bei topischer Medikamentenapplikation an die Rundfenstermembran. Laryngorhinootologie 2004. [DOI: 10.1055/s-2004-823305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
42
|
Rodriguez Jorge J, Dalhoff E, Gummer AW, Zenner HP. Neues, hochauflösendes Laservibrometer für Trommelfellschwingungsmessungen bei niedrigen Schallpegeln. Laryngorhinootologie 2004. [DOI: 10.1055/s-2004-823430] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
43
|
Maassen MM, Malthan D, Rodriguez Jorge J, Zenner HP, Stallkamp J, Schwaderer E, Baumann I, Dammann F. Lokale und globale Navigation mit closed Loop Sicherheitstechnologie für computer- und roboterassistierte Operationen an der lateralen Schädelbasis. Laryngorhinootologie 2004. [DOI: 10.1055/s-2004-823419] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
44
|
Wagner W, Kühn M, Vonthein R, Tisch M, Janssen T, Zenner HP. Zusammenhang zwischen olivocochleärer Aktivität und Lärmvulnerabilität. Laryngorhinootologie 2004. [DOI: 10.1055/s-2004-823204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
45
|
Rodriguez Jorge J, Zenner HP, Baumann I, Maassen MM. Laserdopplervibrometrische Bestimmung der optimalen Vorlast bei MET (Otologics)-Ankopplung. Laryngorhinootologie 2004. [DOI: 10.1055/s-2003-818900] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
46
|
Plontke S, Siedow N, Hahn H, Wegener R, Zenner HP, Salt AN. [1D-and 3D- computer simulation for experimental planning and interpretation of pharmacokinetic studies in the inner ear after local drug delivery]. ALTEX 2004; 21 Suppl 3:77-85. [PMID: 15057412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
The local delivery of drugs to the cochlea is a promising alternative to systemic treatment of inner ear disorders. Whilst new drugs are being developed for this purpose, it is important to determine the time course and total dose required for the various target regions within the inner ear. Due to the small fluid spaces of the inner ear and the resulting experimental and analytical difficulties, many animal studies have only obtained one sample per animal. This results in limited information about drug time courses at specific locations in the inner ear. We show here how computer models considering general pharmacokinetic principles and inner ear geometry are used for application of the 3R-principle in animal research while avoiding experimental sampling artefacts. This can be achieved by: (1) careful planning and interpretation of experiments to study pharmacokinetics in the inner ear, (2) optimising volume sampling techniques, (3) facilitating the use of advantageous, continuous sampling methods like microdialysis and (4) developing a 3D-model that will permit consideration of the complex geometry of the inner ear when transferring results from one species to another.
Collapse
Affiliation(s)
- Stefan Plontke
- Klinik für Hals-, Nasen- und Ohrenheilkunde am Universitätsklinikum Tübingen und Hörforschungszentrum D-Tübingen (THRC), Tuebingen.
| | | | | | | | | | | |
Collapse
|
47
|
Schwaderer E, Dammann F, Maassen MM, Malthan D, Stallkamp J, Zenner HP, Claussen CD. Eine Methode zum dreidimensionalen Vergleich zwischen virtuell geplanter und realer Operation am Beispiel der Mastoidektomie. ROFO-FORTSCHR RONTG 2004. [DOI: 10.1055/s-2004-828123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
48
|
Dammann F, Schwaderer E, Malthan D, Stallkamp I, Zenner HP, Claussen CD, Maassen M. CT-basierte Operationsplanung und Simulation von Eingriffen an der lateralen Schädelbasis. ROFO-FORTSCHR RONTG 2004. [DOI: 10.1055/s-2004-827877] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
49
|
Affiliation(s)
- H P Zenner
- Universitäts-Hals-Nasen-Ohren-Klinik, Tübingen.
| |
Collapse
|
50
|
Oh N, Kupka S, Mirghomizadeh F, Arold R, Zimmermann R, Blin N, Zenner HP, Pfister M. [Clinical and molecular genetic analysis of monozygotic twins displaying stapes gusher syndrome (DFN3)]. HNO 2003; 51:629-33. [PMID: 12942177 DOI: 10.1007/s00106-002-0777-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
BACKGROUND DFN3 ( "stapes gusher") is the most frequent form of X-linked hearing impairment. It accounts for up to 0.5% of all cases of severe childhood hearing disorders. PATIENTS AND METHODS Monozygotic twins with suspected stapes gusher syndrome, their mother, and control individuals were analyzed clinically and genetically. RESULTS The clinical investigations confirmed a DFN3 phenotype in both brothers who displayed all typical symptoms. A molecular genetic investigation of the POU3F4 gene, which plays an essential role in the development of DFN3, was also performed. No chromosomal aberrations within the coding region of POU3F4were detected. Since several authors have described mutations in the 5' untranslated region of the gene also resulting in a DFN3 phenotype, we screened this area by microsatellite analysis and detected a double deletion localized in the critical interval. This is the first description of a double deletion in the non-coding region of POU3F4 leading to DFN3 phenotype. CONCLUSION Interestingly, in spite of having an identical genotype, the twins displayed significant phenotypic differences. This underlines the importance of exogenous factors in the development of inherited pathological processes.
Collapse
Affiliation(s)
- N Oh
- Hals-Nasen-Ohren-Klinik der Universität Tübingen
| | | | | | | | | | | | | | | |
Collapse
|